Several antidepressants are potent inhibitors of cytochrome P450 2D6 liver enzymes (CYP2D6) and can increase the plasma concentrations of certain β-blockers when administered concomitantly, potentially leading to serious medical consequences such as hypotension, bradycardia, and falls.
Eligible patients were using β-blocker medications that are primarily CYP2D6 substrates (e.g., metoprolol, propranolol, or carvedilol). A total of 21,292 people met the inclusion criteria, and 4.3% of patients required hospitalization or ED (emergency department) visits within 30 days of co-medication (with antidepressants). Patients receiving antidepressants with moderate to strong CYP2D6 inhibitory potential (fluoxetine, paroxetine, duloxetine, or bupropion) had a greater risk for hospitalization or ED visits for hemodynamic events than those initiated on antidepressants with weak CYP2D6 inhibition for 30 days or less when each was compared with patients receiving no antidepressants (hazard ratio 1.53. Other demographic variables associated with increased morbidity included advanced age, male sex, higher β-blocker doses, and African American race or Hispanic ethnicity.
Antidepressants And Beta-Blockers
Posted 01 July 2020 - 04:51 PM
0 user(s) are reading this topic
0 members, 0 guests, 0 anonymous users